Allergy Therapeuti (AGYTF) Stock Rating Upgraded by Zacks Investment Research
Allergy Therapeuti (NASDAQ:AGYTF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “Allergy Therapeutics Plc is a specialty pharmaceutical company focused on allergy vaccination. The company’s product pipeline consists of PollinexTrees(R), Pollinex Grasses + Rye(R), Skin Prick Testing, Diagnostic Products and Service. Allergy Therapeutics Plc is based in Worthing, the United Kingdom. “
Allergy Therapeuti (NASDAQ:AGYTF) opened at 0.39 on Wednesday. The firm has a 50-day moving average price of $0.39 and a 200 day moving average price of $0.39. Allergy Therapeuti has a 1-year low of $0.39 and a 1-year high of $0.39. The stock’s market cap is $231.44 million.
Receive News & Stock Ratings for Allergy Therapeuti Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeuti and related stocks with our FREE daily email newsletter.